Compare ANL & SAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ANL | SAR |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.5M | 372.7M |
| IPO Year | 2022 | N/A |
| Metric | ANL | SAR |
|---|---|---|
| Price | $15.68 | $22.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | $16.00 | ★ $23.75 |
| AVG Volume (30 Days) | ★ 350.7K | 108.1K |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 14.48% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.39 |
| P/E Ratio | ★ N/A | $9.44 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $20.78 |
| 52 Week High | $13.00 | $25.64 |
| Indicator | ANL | SAR |
|---|---|---|
| Relative Strength Index (RSI) | 80.26 | 55.08 |
| Support Level | $1.36 | $22.56 |
| Resistance Level | N/A | $23.12 |
| Average True Range (ATR) | 1.38 | 0.58 |
| MACD | 0.70 | 0.14 |
| Stochastic Oscillator | 99.31 | 97.07 |
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.